Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Institutional clients can use cUSDO, OpenEden Digital’s yield-bearing digital asset, as collateral on MirrorRSV while ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Researchers at Washington University School of Medicine in St. Louis have revealed the structure of a key protein involved in ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds—ticks.

In a twist, researchers at the University of Virginia and the National Institutes of Health uncovered a new organelle, dubbed the hemifusome. This tiny membrane-bound structure serves as a cellular ...

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.